DOI:
10.1055/s-00000004
Aktuelle Neurologie
LinksClose Window
References
Batchelor TT, Duda DG, di Tomaso E et al.
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Clin Oncol 2010;
28: 2817-2823
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.